ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008

ACADIA to Host Conference Call and Webcast on Wednesday, November 5, 2008, at 5:00 p.m. Eastern Time

SAN DIEGO–(BUSINESS WIRE)–Oct. 29, 2008–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2008 on Wednesday, November 5, 2008, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, November 5, 2008, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and development programs.

The conference call may be accessed by dialing 800-435-1261 for participants in the U.S. or Canada and 617-614-4076 for international callers (reference passcode 29663518). A telephone replay of the conference call may be accessed through November 19, 2008 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 10534976). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there until November 19, 2008.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is focused on developing a portfolio of its four most advanced product candidates, including pimavanserin in Phase III for Parkinson’s disease psychosis, a compound in Phase II for chronic pain and a compound in Phase I for glaucoma, both in collaboration with Allergan, and ACP-106 in IND-track development. All of the product candidates in ACADIA’s pipeline emanate from discoveries made using its proprietary drug discovery platform and are directed at indications with large unmet medical needs. ACADIA’s corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.

CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871

SOURCE: ACADIA Pharmaceuticals Inc.